ProteoCool Pills#10: Use of 2F-Peracetyl-Fucose to produce low fucosilated monoclonal antibodies with Expi293 and ExpiCHO cell lines

Therapeutic monoclonal antibodies are the fastest growing class of therapeutics for the treatment of various cancers and inflammatory disorders. The Fc region of human IgG antibodies interacts with multiple Fcγ receptor (FcγR) and complement proteins and mediates immune effector functions, which are important for many therapeutic applications, e.g. elimination of targeted cells via antibody-dependent cellular-cytotoxicity (ADCC), -phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC).

To date, therapeutic IgG antibodies (either approved or in clinical development) belong to the IgG1, IgG2 or IgG4 subclasses. Each IgG isotype has a distinct binding affinity to the various FcγRs, which are expressed differently on immune cells. 

In cancer immunotherapy, some IgG1 antibodies (eg ipilimumab) rely on the Fc-mediated immune effector function, dependent cellular cytotoxicity (ADCC), as the major mode of action to deplete tumor cells.

It is well-known that this effector function is modulated by the N-linked glycosylation (N297) in the Fc region of the antibody.

In fact, if the N297A mutation  is able to reduced FcγR-binding and abolish ADCC activity on the other hand,  the absence of core fucose on the Fc N-glycan has been shown to increase IgG1 Fc binding affinity to the FcγRIIIa present on immune effector cells such as natural killer cells and lead to enhanced ADCC activity.

Various strategies have focused on producing afucosylated antibodies to improve therapeutic efficacy. While engineering of the cell lines (eg FUT8 deletion: @Potelligent or @GlymaxX Technologies) are required for scale up production of recombinant afucosilated mabs, for small lab scale for production of mgs, the supplementation of 2F-Peracetyl-Fucose is a simple and efficient solution to produce “low fucosilated mabs” to be used in functional in vivo and in vitro assay.

Media supplementation with 200 µM of  2F-Peracetyl-Fucose allow to produce low fucosilated mabs with transient transfection in Expi293 or ExpiCHO cells) just before cell transfection (as reported on Chakraborty et.al for the Expi293 cells) allow to produce a mab with low fucosilation level (as reported in Fig1) and enhanced ADCC activity.

n.b: The results of ELISA assay on mabs produced from Expi293 and ExpiCHO seem to suggest that the ExpiCHO show a decreased fucosilation level respect than Expi293 also in absence of the 2F paracetyl fucose. 

Preparation of 2F-Peracetyl-Fucose stock solution:

2F-Peracetyl-Fucose is supplied as powder (10mg). It can be directly resuspended in the glass bottle with 1mM DMSO to obtain a 34.2mM stock solution (171X) that could be stored at -20°C.

584µl of 34.2mM of 2F-Peracetyl-Fucose were added to 100 ml of cells just before the transient transfection with Expifectamines

Prons:

Very Simple!!

Concerns:

Expensive: Cost of  2F-Peracetyl-Fucose: ~ 1000euro/liter of transfection make this approach feasible only for small lab scale productions